CYP17 polymorphisms and prostate cancer outcomes

Keyphrases

• Polymorphism 100%
• Prostate Cancer Outcomes 100%
• CYP17 100%
• CYP17 Gene 100%
• Prostate Cancer 66%
• Single nucleotide Polymorphism 66%
• Prostate Cancer Risk 66%
• Prostate Cancer Survival 66%
• Hazard Ratio 33%
• Genotype 33%
• Medical Records 33%
• Risk Reduction 33%
• Conflicting Results 33%
• Gene Variants 33%
• Disease Progression 33%
• Biosynthesis Pathway 33%
• Genetic Variation 33%
• Patient Outcomes 33%
• Cox Regression Analysis 33%
• Cause-specific Mortality 33%
• Population-based Case-control Study 33%
• Washington 33%
• Patient Survey 33%
• Survey Data 33%
• Advanced Prostate Cancer 33%
• SEER Cancer Registry 33%
• C-17 33%
• Androgen Biosynthesis 33%
• Cytochrome P450 17 33%
• 17α-Hydroxylase 33%
• 17,20-Lyase 33%
• King County 33%
• Regulatory Regions 33%

Biochemistry, Genetics and Molecular Biology

• Single-Nucleotide Polymorphism 100%
• Cancer Survival 100%
• Allele 50%
• Genetic Divergence 50%
• Cancer Registry 50%
• Case-Control Study 50%
• Oxygenase 50%
• Enzyme 50%
• Genetic Variation 50%
• Regulatory Region 50%
• Cytochrome P450 50%
• Cancer Mortality 50%
• Medical Record 50%
• Risk Reduction 50%
• Lyase 50%
• Androgen Synthesis 50%